住院在重症监护室的COVID-19患者的临床和甲状腺特征
N Macías-Gómez1, O Montañez-Valdez, E Leal-Ugarte
1Laboratorio de Genética Humana, Centro Universitario del Sur, Universidad de Guadalajara, Ciudad Guzmán, Jalisco, México.
European review for medical and pharmacological sciences
|September 26, 2023
概括
COVID-19 ICU 患者经常表现出甲状腺功能障碍,特别是低 TSH 和 FT3. 没有接种疫苗,超重/肥胖的患者具有高甲的水平表明预后不佳,死亡风险增加.
科学领域:
- 内分泌学 在内分泌学.
- 传染性疾病 传染性疾病
- 关键护理医学 关键护理医学
背景情况:
- COVID-19可以影响包括甲状腺在内的各种身体系统.
- 严重患有COVID-19患者的甲状腺功能变化需要进一步调查.
研究的目的:
- 研究COVID-19患者的重症监护室 (ICU) 甲状腺功能的流行病学和临床特征.
- 在这个患者队列中确定预后不佳和死亡率的潜在预测因素.
主要方法:
- 一项对63名COVID-19的ICU患者进行的横截面研究.
- 评估甲状腺激素 (TSH,T4,T3,FT3),并发症 (糖尿病,高血压,BMI) 和生物标志物 (前素,C反应蛋白).
主要成果:
- 87%的患者表现出甲状腺激素轴的改变,主要是低TSH和FT3.
- 较低的TSH (0.56±0.79) 和FT3 (2.34±0.52) 显著流行.
- 增加的前素 (PCT) 度与更高的死亡风险有关 (p=0.0001).
结论:
- 低TSH和FT3的COVID-19患者,未接种疫苗的状态,超重/肥胖和高PCT水平面临更糟糕的预后.
- 这些因素可能是严重COVID-19病例死亡风险增加的指标.
相关概念视频
Myocarditis II: Clinical Features and Diagnostic Tests
12
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
12
Acute Coronary Syndrome III: Diagnostic Studies
9
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
9
Acute Respiratory Failure-II
263
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
263
Acute Respiratory Failure-I
231
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
231
Acute Respiratory Failure-III
209
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
209
Acute Kidney Injury III: Clinical Manifestations
15
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
15


